These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 16314820)

  • 21. Immunization. Update: search for an AIDS vaccine.
    Bende S; Johnston MI
    AIDS Read; 2000 Sep; 10(9):526-32, 534-8. PubMed ID: 11019448
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Progress toward an HIV vaccine.
    Letvin NL
    Annu Rev Med; 2005; 56():213-23. PubMed ID: 15660510
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytotoxic T-lymphocyte responses to canarypox vector-based HIV vaccines in HIV-seronegative individuals: a meta-analysis of published studies.
    Edupuganti S; Weber D; Poole C
    HIV Clin Trials; 2004; 5(5):259-68. PubMed ID: 15562366
    [TBL] [Abstract][Full Text] [Related]  

  • 24. AIDS vaccine development: the long and winding road.
    Garber DA; Feinberg MB
    AIDS Rev; 2003; 5(3):131-9. PubMed ID: 14598562
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIV preventive vaccines. Progress to date.
    Esparza J; Osmanov S; Heyward WL
    Drugs; 1995 Nov; 50(5):792-804. PubMed ID: 8586027
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
    Shen X; Basu R; Sawant S; Beaumont D; Kwa SF; LaBranche C; Seaton KE; Yates NL; Montefiori DC; Ferrari G; Wyatt LS; Moss B; Alam SM; Haynes BF; Tomaras GD; Robinson HL
    J Virol; 2017 Dec; 91(24):. PubMed ID: 29021394
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Simultaneous approach using systemic, mucosal and transcutaneous routes of immunization for development of protective HIV-1 vaccines.
    Belyakov IM; Ahlers JD
    Curr Med Chem; 2011; 18(26):3953-62. PubMed ID: 21824096
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prospects for an AIDS vaccine: three big questions, no easy answers.
    Garber DA; Silvestri G; Feinberg MB
    Lancet Infect Dis; 2004 Jul; 4(7):397-413. PubMed ID: 15219551
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans.
    Pissani F; Schulte B; Eller MA; Schultz BT; Ratto-Kim S; Marovich M; Thongcharoen P; Sriplienchan S; Rerks-Ngarm S; Pitisuttithum P; Esser S; Alter G; Robb ML; Kim JH; Michael NL; Streeck H
    J Virol; 2018 Dec; 92(23):. PubMed ID: 30209165
    [TBL] [Abstract][Full Text] [Related]  

  • 30. No vaccine against HIV yet--are we not perfectly equipped?
    Singh M
    Virol J; 2006 Aug; 3():60. PubMed ID: 16939652
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Vaccines against HIV].
    Holm-Hansen C
    Tidsskr Nor Laegeforen; 2006 Nov; 126(23):3117-20. PubMed ID: 17160118
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An HIV vaccine: how and when?
    Esparza J
    Bull World Health Organ; 2001; 79(12):1133-7. PubMed ID: 11799445
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of an epitope-based HIV-1 vaccine strategy from HIV-1 lipopeptide to dendritic-based vaccines.
    Surenaud M; Lacabaratz C; Zurawski G; Lévy Y; Lelièvre JD
    Expert Rev Vaccines; 2017 Oct; 16(10):955-972. PubMed ID: 28879788
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of a Live Recombinant BCG Expressing Human Immunodeficiency Virus Type 1 (HIV-1) Gag Using a pMyong2 Vector System: Potential Use As a Novel HIV-1 Vaccine.
    Kim BJ; Kim BR; Kook YH; Kim BJ
    Front Immunol; 2018; 9():643. PubMed ID: 29636755
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mucosal immunity and HIV-1 infection: applications for mucosal AIDS vaccine development.
    Belyakov IM; Ahlers JD
    Curr Top Microbiol Immunol; 2012; 354():157-79. PubMed ID: 21203884
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DNA prime/MVTT boost regimen with HIV-1 mosaic Gag enhances the potency of antigen-specific immune responses.
    Liu W; Wong YC; Chen SMY; Tang J; Wang H; Cheung AKL; Chen Z
    Vaccine; 2018 Jul; 36(31):4621-4632. PubMed ID: 29961605
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progress in HIV vaccine development.
    Hsu DC; O'Connell RJ
    Hum Vaccin Immunother; 2017 May; 13(5):1018-1030. PubMed ID: 28281871
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of neutralizing antibodies in protective immunity against HIV.
    Srivastava IK; Ulmer JB; Barnett SW
    Hum Vaccin; 2005; 1(2):45-60. PubMed ID: 17038830
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heterologous prime-boost vaccination strategies for HIV-1: augmenting cellular immune responses.
    Newman MJ
    Curr Opin Investig Drugs; 2002 Mar; 3(3):374-8. PubMed ID: 12054082
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Obstacles and progress toward development of a preventive HIV vaccine.
    Heyward WL; MacQueen KM; Jaffe HW
    J Int Assoc Physicians AIDS Care; 1997 Aug; 3(8):28-34. PubMed ID: 11364630
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.